HB1139Enacted
Allow individualized investigative treatments for patients with life-threatening or debilitating diseases or conditions.
This bill expands access to experimental treatments for patients with life-threatening or severely debilitating diseases by allowing them to try investigative drugs and treatments—including personalized treatments based on their genetic makeup—if they've exhausted FDA-approved options and their doctor recommends it. The law creates new eligibility requirements and protections, including informed consent and physician attestation, while removing previous restrictions on who can receive these experimental treatments. This is sometimes called "right to try" legislation, giving terminally ill patients another potential avenue when standard treatments have failed.